A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind placebo-controlled study comparing different doses of
bryostatin for the treatment of moderately severe to severe Alzheimer's disease. The study is
15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose
of study drug.